Af­ter ground­break­ing year for RSV ap­provals, GSK looks to mod­el pe­di­atric suc­cess for adult vac­cines

In vac­cine de­vel­op­ment, 2023 will be re­mem­bered for ma­jor strides in RSV with the first-ever ap­provals and now three dif­fer­ent op­tions. While that’s good news for pub­lic health, ac­tu­al RSV vac­cine up­take among adults is off to a slow start. On­ly about 15% of Amer­i­cans aged 60 and old­er have got­ten RSV shots so far, ac­cord­ing to CDC da­ta.

GSK, one of two drug­mak­ers of adult RSV vac­cines along with Pfiz­er, is tak­ing a pol­i­cy ap­proach fo­cused on lo­cal com­mu­ni­ties. It hopes to mir­ror the same kind of suc­cess­es, like rou­tine sched­ul­ing and wide­spread ac­cess, preva­lent in pe­di­atric care.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER